Interplay Bio utilizes its LigandPro Platform to accelerate the development of Targeted Protein Degradation (TPD) drugs. This platform identifies ligands that bind to any protein surface, enabling the targeting of previously undruggable proteomes. The company offers services for target ligand discovery, development of novel E3 Ligase binders, and molecular glues for therapeutic applications.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery for targeted protein degradation (TPD) and drug repurposing is often slow and inefficient due to the difficulty in identifying small molecule-target interactions on a large scale. Traditional methods struggle to identify ligands that bind to non-traditional druggable pockets, limiting the ability to target the undruggable proteome. Current screening methods also lack the ability to fully exploit the polypharmacology of drugs, hindering the optimization of safety profiles and dosage.
Solution
Interplay Bio's LigandPro platform accelerates TPD drug development and drug repurposing by enabling large-scale phenotypic screening of small molecule-target interactions. LigandPro identifies ligands that bind to any protein surface, including traditionally undruggable targets, by leveraging existing protein libraries for rapid small molecule hit identification. The platform's hypothesis-free approach enables exploration of a wide range of protein targets, increasing the possibility of finding new hits, even for difficult-to-drug proteins. LigandPro also facilitates the rational expansion of molecular glue degraders, achieving higher specificity and safety profiles.
Target Audience
Interplay Bio's primary customers are pharmaceutical companies seeking to develop and commercialize TPD drug candidates, as well as organizations looking to repurpose existing molecule libraries.
Features
- Identification of ligands that bind to any protein surface, including non-traditional druggable pockets.
- Rapid screening against a vast array of potential targets using existing protein libraries.
- Hypothesis-free approach to explore a wide range of protein targets.
- Identification and exploitation of drug polypharmacology to target multiple related proteins.
- Discovery of new E3 ligase binders and molecular glues.
- Screening of small molecules for binding with specific targets.
- Identification of 100+ protein interactions of interest from FDA-approved small molecules.